Dr. Scott Rocklage has been making a lot of headway in the fight against Myotonic dystrophy type I via his company 5AM Ventures private company Expansion Therapeutics. It recently closed Series A financing totaling more than $50 million. Expansion Therapeutics mission is the advanced treatment of specific genetic disorders using small molecule drugs targeting key human disease-driving RNAs. In particular, genetic disorders like muscular dystrophy, symptoms only begin to present themselves when RNA reaches toxic levels.
When the body is fully healthy and functioning properly RNA molecules are harmlessly transferred from DNA and become protein. However, these molecules can become quite toxic if the body’s production gets out of hand. When the toxin level drastically increase inside the cells Myotonic dystrophy type I occurs as a result. The condition can affect the entire body, including the central nervous system. Because it is genetic multiple individuals in a family may suffer from the disorder.
Many believe with Dr. Scott Rocklage at the helm Expansion Therapeutics may lead the way in curing the damaging disorder. This would be a huge win for the medical world as it currently has no reliable treatment for Myotonic dystrophy type I.
Dr. Scott Rocklage joined 5AM Ventures in the early 2000’s and worked his way from venture partner to managing partner in a year’s time. He was a welcomed addition to %AM Ventures team as he possesses decades of experience in healthcare management.
Since he was a young man Rocklage was always very ambitious. He attended both the the University of California, Berkeley and the Massachusetts Institute of Technology (MIT) earning degrees from both educational institutions. A lesser known quality of Rocklage is his creativity. He owns more than 30 patents as an inventor. Not to mention h’s an accomplished author with dozens of published work.
Visit http://5amventures.com/team/scott-m-rocklage-phd/ to learn more.